News

Viyash Scientific Limited, formerly Sequent Scientific Limited, announced that its Nomination and Remuneration Committee has approved the allotment of 11,07,309 equity shares following the exercise of stock options under the Sequent Scientific Limited Employee Stock Option Plan 2020 and the Viyash Scientific Limited Employee Stock Option Scheme 2026; 9,26,333 shares were allotted at a price of Rs. 86 per share and 1,80,976 shares at Rs. 101 per share.

Viyash Scientific Limited, formerly Sequent Scientific Limited, announced that its Nomination and Remuneration Committee approved the allotment of 6,12,773 equity shares, comprised of 2,30,001 shares at a price of Rs 86 per share under the Sequent Scientific Limited Employee Stock Option Plan 2020 and 3,82,772 shares at a price of Rs 101 per share under the Viyash Scientific Limited Employee Stock Option Scheme 2026. The allotment increased the company’s issued and paid-up equity share capital from Rs 87,98,15,176 consisting of 43,99,07,588 equity shares to Rs 88,10,40,722 consisting of 44,05,20,361 equity shares.

Viyash Scientific Ltd share price softened by 1.19% to Rs 273.8. The Company`s net profit rose by 19.45% to Rs 79.29 crore, while revenue from operations slightly gained 2.87% to Rs 946.36 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, gaining 4.63%. It has improved by 0.56% over last one week and heading higher by 13.27% in last one month while the market capitalization of Viyash Scientific Ltd has inched up 2.76% and 21.93% in the same period respectively. Profit before tax (PBT) of Viyash Scientific Ltd stood at Rs 112.41 crore in Q2 FY26, expanding by 132.54% year-on-year, and dropping 10.24% quarter-on-quarter. EBITDA came in at Rs 170 crore, rallying 51.94% YoY and easing 1.03% sequentially. Total expenses posted a minor rise of 4.22% to Rs 829.75 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 402.34 crore, going up by 10.56% YoY, while employee benefits expense was at Rs 162.65 crore, rising by 8.56% YoY. For the TTM ended FY26, revenue from operations grew 13.75% to Rs 3420.31 crore, while net profit surged by 1324.54% to Rs 224.65 crore, compared to previous TTM. EBITDA jumped by 34797% to Rs 608.98 crore, and PBT jumped 2548.10% to Rs 349.02 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 322.91 crore in FY26, as against Rs 344.8 crore in FY25. Viyash Scientific Ltd soared by 54.86% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.56% during the same period.

Viyash Scientific will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Viyash Scientific announced that the 41th Annual General Meeting(AGM) of the company will be held on 11 August 2026.